S1PR1 and myeloid sarcoma: In clinical trials with another oral sphingosine-1-phosphate receptor 1 and 5 modulator, ozanimod, in patients with relapsing MS, both systolic and diastolic blood pressure slight increases, detectable 3 months after treatment initiation, have been demonstrated [22].